Fear Merchants

Fear Merchants 6-Minute Preview

Forrest Maready
15.7K subscribers
28,975 views Apr 18, 2020

As the world is gripped with apprehension over coronavirus, there is growing concern that a group of government, humanitarian, and pharmaceutical stakeholders are conspiring together to establish more complete global control. With programs like ID2020 and Agenda2032, these agencies have publicized their intentions for all to see. At the same time, world health organizations are using the coronavirus panic to forward their agenda of immunity cards and mandatory vaccinations for all. These concepts, once considered conspiracy theory, are now being openly discussed by those very people who until recently denied such goals.

To accomplish this task, they have become experts in creating the one things which allows most humans to be more easily controlled: fear. Just like the church did for the previous thousand years, these groups are gaining control and financial power by purposefully inciting fear and panic in the population. Some are waking up and have become aware they were being manipulated.

WHAT IS MAN-MADE DISEASE?
Some of the diseases they have made us afraid of were their own creations, unwittingly conceived in laboratories across the world. Others were purposefully created to cause suffering to as many people as possible. Polio, autism, Zika, AIDs, some cancers, and many other illnesses that plague our world today are the direct result of scientists and doctors around the world, many unaware of the harm they would end up causing.

Unfortunately, there is a dark side to this wickedness. The most innocent of humanity—children—are often caught in the middle, purposefully sacrificed upon the altar of science and medicine, their parents, oblivious to the twisted rituals they allow to be performed on them. Coupled with recent revelations about the nature of child trafficking and spiritual warfare, knowing that the practice of childhood vaccination—with the fear, immobilization, and restraint required to perform these acts—is largely unnecessary and often creates more disease than it prevents has caused many parents to abandon the practice altogether.

How much does Medical School teach about Vaccines? [My Incredible Opinion]

Forrest Maready
15.7K subscribers
18,086 views Jul 28, 2016

How much do Medical students learn about vaccines in medical school? You might be surprised!

The Smile Difference: Autism vs. Asperger Syndrome

Forrest Maready
15.7K subscribers
54,127 views Aug 15, 2020

Since autism was first described in the 1940s, parents and doctors have been trying to understand the differences between autism and Asperger syndrome. Are they the same thing or something entirely different?

Independent researcher Forrest Maready talks about an interesting component of his "Crooked Theory" that highlights the actual difference undermining autism and Asperger syndrome—a difference so dramatic you can see it on people's faces.

Century-Old Drug Tested in Boys with Autism

UC San Diego Health
109K subscribers
92,481 views May 26, 2017

Suramin is a 100-year-old drug developed to treat African sleeping sickness. It is not approved for any therapeutic use in the U.S. However, a small clinical trial at UC San Diego School of Medicine found that a single intravenous dose of suramin produced measurable, but transient, improvements in five boys with autism spectrum disorder (ASD). More broadly, the trial findings support the “cell danger response theory,” which posits that autism is driven by metabolic dysfunction — and thus treatable. Larger, longer clinical trials are needed to assess suramin as an ASD treatment.

In this video, we hear from lead researcher Robert Naviaux, MD, PhD, and the mothers of two boys who received suramin in the trial.

BRAIN Foundation Presents: Suramin for Autism in 2023 and Beyond, with Howard Weisman CEO, PaxMedica

The BRAIN Foundation
3.31K subscribers
21,081 views Jun 23, 2023 #philanthropy

An exclusive interview on the latest developments and plans for FDA approval for suramin, a potential breakthrough treatment for autism.
Howard Weisman CEO, PaxMedica shares with us a detailed update on the development of suramin as an evidence-based therapeutic for autism, clinical trial results, go-forward plans to seek FDA approval, international availability, and the possibility of expanded access for compassionate use for autism.

00:04:40 - Introduction - about The BRAIN Foundation
00:06:10 - Howard Weisman’s journey and becoming PaxMedica CEO
00:09:01 - About purinergic signaling, Dr Naviaux’s Cell Danger Response theory and its relevance to autism
00:11:50 - First study in of suramin in children with autism carried shows significant reduction in core autism symptoms, inspires creation of PaxMedica
00:13:20 - Repurposing a hundred year old antiparasitic drug - overcoming regulatory challenges
00:18:40 - The second part of the big challenge: mass-producing suramin to ensure a steady supply
00:21:00 - About the second suramin in autism study that took place in 2020 in South Africa, and what was learnt from is
00:27:30 - Tracking changes in autism clinical trials - the differences in measuring symptoms in the South African trial vs Dr Naviaux original suramin study
00:32:30 - 2021 onwards - advancing PaxMedica’s program, raising funds, planning mass production of suramin and the next clinical trial for autism
00:35:47 - Timeline for obtaining FDA approval for suramin drug approval
00:42:25 - Exploring drug safety and potential risks
00:46:00 - Approving suramin outside the US and the possibility for extended/compassionate use
00:53:35 - The importance of community input for PaxMedica’s mission
00:55:40 - Announcement: new placebo-controlled clinical trial to take place in South Africa
01:03:36 - Raising funds to support treatment trials and how PaxMedica plans to reach its goals
01:09:09 - Live audience Questions & Answers
01:20:22 - Alternative compounds with antipurinergic effects and the upcoming Neuromodin™ clinical trial
01:27:55 - What else is happening in autism research and science and why attend

ABOUT SURAMIN:
a 100 year old drug that has been traditionally used to treat African sleeping sickness and river blindness. In addition to its antiparasitic action, suramin is also a non-selective inhibitor of purinergic signaling, or in other words, an antipurinergic drug.

The Naviaux Lab at University of California, San Diego led by Robert K. Naviaux, MD, PhD, discovered that the unique properties of suramin made it the first in a new class of drugs that could be used to test the cell danger response (CDR) hypothesis for the origin and treatment of Autism Spectrum Disorder (ASD). Suramin successfully improved all the core symptoms of ASD and the metabolic and GI abnormalities in both animal models and a small human clinical trial.

ABOUT SURAMIN CLINICAL TRIALS
This human clinical trial, published in 2017, was a small, randomized Phase 1 study of low-dose suramin in 10 children with ASD. The results demonstrated that a single intravenous dose of suramin improved core symptoms of autism in the five children who received the drug, compared to placebo. The improvements were noted in the domains of language, social interaction, and repetitive behaviors.

This study was followed by PaxMedica’s Phase 2 trial of Pax-101 (IV suramin) for ASD, the results of which were presented to AACAP in October 2021. This study was a dose-ranging, randomized, double-blind, placebo-controlled, multi-dose trial evaluating the safety and efficacy of suramin in 52 children with moderate to severe autism across 6 sites in South Africa.

ABOUT PAXMEDICA
PaxMedica is a clinical-stage biopharmaceutical company developing innovative treatments for unmet needs in neurodevelopmental disorders, including ASD.

🎥 This talk was part of was part of BRAINTalk Webinar Series by the BRAIN Foundation
🎥 For more BRAINTalk Webinars see: • BRAIN Community Webinars

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

The BRAIN Foundation https://brainfoundation.org/ is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.